Histogenics (HSGX) Misses Q3 EPS by 21c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/1/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. GILD
9. SBUX
10. SNDK

Go back to Histogenics (HSGX) Misses Q3 EPS by 21c

Histogenics Corporation Announces Third Quarter 2016 Financial and Operating Results

November 10, 2016 6:30 AM EST

- NeoCart® Phase 3 Clinical Trial More than 75% Enrolled -- Enrollment On-Track to Complete by End of Second Quarter of 2017 -- Third Quarter Financing Expected to Fund Company to Phase 3 Data -- Company to Host Conference Call and Webcast Today at 8:30 a.m. EST -

WALTHAM, Mass., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced its financial and operational results for the quarter ended September 30, 2016. 

... More